Brief: Tryptamine Therapeutics Secures A$2.6M In Non-Dilutive Capital To Fast Track Trp-8803 Clinical Development
Aug 12 (Reuters) - Tryptamine Therapeutics Ltd TYP.AX: A$2.6M IN NON-DILUTIVE CAPITAL SECURED TO FAST TRACK TRP-8803 CLINICAL DEVELOPMENT Further company coverage: TYP.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entropy Neurodynamics
See all newsBrief: Entropy Neurodynamics Seeks Trading Halt
Brief: Entropy Neurodynamics Says Strategic Agreement Signed With CDMO Biocina
Brief: Entropy Neurodynamics Secures HREC Approval For Phase 1B/2A 8-Indication Basket Study Of TRP-8803
Brief: Entropy Neurodynamics Requests Trading Halt
Brief: Entropy Neurodynamics Seeks Trading Halt